




Molecular Genetics

UNIVERSITY OF TORONTO



KRAS is frequently mutated in cancer, and its deregulation is associated with a poor prognosis as well as therapeutic resistance. Despite decades of intense efforts, KRAS is still deemed "undruggable", warranting the need for alternative therapeutic approaches. Using a chemoproteomic method, we assessed changes at the cell surface occurring in response to oncogenic KRAS. Our results indicate that KRAS massively reprograms the epithelial cell surface, and highlights potential tumor biomarkers and/or therapeutic targets for KRASdependent cancers

## Dr. Philippe P. Roux

Associate Professor of Pathology and Cell Biology University of Montreal

Host: Dr. Andrew Emili

Date: Thursday February 23<sup>rd</sup>, 2017 Time: 11AM Place: Medical Sciences Building 1 King's College Circle Room 4171